IADVL
Indexed with PubMed and Science Citation Index (E) 
 
Users online: 4996 
     Home | Feedback | Login 
About Current Issue Archive Ahead of print Search Instructions Online Submission Subscribe What's New Contact  
  Navigate here 
  Search
 
   Next article
   Previous article 
   Table of Contents
  
 Resource links
   Similar in PUBMED
    Search Pubmed for
    Search in Google Scholar for
  Related articles
   [PDF Not available] *
   Citation Manager
   Access Statistics
   Reader Comments
   Email Alert *
   Add to My List *
* Registration required (free)  

 
  In this article
   Abstract
   Introduction
   Subjects and Methods
   Results
   Comments
   References
   Article Tables

 Article Access Statistics
    Viewed4145    
    Printed46    
    Emailed1    
    PDF Downloaded0    
    Comments [Add]    
    Cited by others 1    

Recommend this journal

 


 
SHORT COMMUNICATION
Year : 1993  |  Volume : 59  |  Issue : 2  |  Page : 71-73

Oral acyclovir in recurrent genital herpes




Correspondence Address:
R K Pandhi


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

  Abstract 

Recurrent genital herpes (RGH) is a difficult condition to treat. Oral acyclovir therapy has been shown to have a definite role in suppressing the recurrent episodes of the disease. Most studies, however, are available from the West. We report our experience with oral acyclovir therapy. Ten patients of RGH with more than 8 episodes/year received acylovir in the dose of 200 mg thrice daily for 6 months. They were followed up for a period ranging from 6 months to 3.5 years. Eight patients stayed symptom-free while on therapy and during the follow-up period. One patient showed a recurrence while on treatment and another 4 months after stopping treatment. No adverse effects were seen in any of the patients.


Keywords: Acyclovir, Genital Herpes


How to cite this article:
Pandhi R K, Mittal A, Gupta L. Oral acyclovir in recurrent genital herpes. Indian J Dermatol Venereol Leprol 1993;59:71-3

How to cite this URL:
Pandhi R K, Mittal A, Gupta L. Oral acyclovir in recurrent genital herpes. Indian J Dermatol Venereol Leprol [serial online] 1993 [cited 2020 Feb 21];59:71-3. Available from: http://www.ijdvl.com/text.asp?1993/59/2/71/3888



  Introduction Top


Recurrent genital herpes (RGH) causes pain and discomfort, disrupts sexual relations and can result in considerable emotional trauma. Until recently, little could be done to help these patients. However, the introduction of acyclovir has made considerable impact on treatment of genital herpes. Acyclovir is not only effective in primary genital herpes but has been used successfully for the management of recurrent episodes as well. [1],[2],[3],[4][5],[6]sub To the best of our knowledge, no study on the efficacy of acyclovir in RGH is available from India. We report our experience with suppressive oral acyclovir therapy in patients of RGH.


  Subjects and Methods Top


Ten patients (9 male, 1 female) of RGH were included in the study. The clinical profile of patients is shown in Table I. All the patients presented with either grouped vesicular lesions or superficial tiny ulcers / erosions on genitals and had a history of similar lesions occurring in the past. Tzanck smear for intranuclear inclusion was positive in all of them. All patients had minimum of 6 recurrences of RHG in the preceding year and they were not receiving any active antiviral treatment during the past 1 month. The presence of any other concomitant STD was excluded by a thorough clinical examination, negative VDRL and ELISA test for HIV antibodies. Other exclusion criteria included pregnancy, patients with impaired renal functions and those unable to attend the follow-up at required intervals. After obtaining their informed consent, the patients were given oral acyclovir 200 mg 5 times a day during the acute episode for 7 days, followed by 200 mg 8 hourly for 6 months. Patients were evaluated every month for a period ranging from 1 to 3-1/2 years (average 2.5 years). Complete haemogram, blood urea, serum electrolytes and creatinine, and liver function tests were done before starting the treatment and then at every subsequent visit.


  Results Top


Eight out of 10 patients showed a remarkable improvement with acyclovir. There was no recurrence of lesions in these patients while on treatment and after the stoppage of therapy. All these patients stayed symptom-free during the follow-up period of 1 year to 3.5 years. Two patients developed recurrence; 1 while on treatment and the other 4 months after stoppage of therapy. In both these patients, the recurrence possibly followed the consumption of alcohol. These recurrences were mild in nature and were controlled with topical acyclovir therapy. None of the patients showed any adverse effects during the course of therapy.


  Comments Top


Genital herpes is a recurrent disease, the satisfactory treatment of which still eludes us. Studies, mostly from the West have shown that suppressive therapy has a definite role in the management of RGH. [1],[2[,[3],[4][5],[6] In the present study, 8 / 10 patients with suppressive acyclovir therapy did not have any recurrence of herpetic lesions while on therapy. The patients remained free of recurrences for prolonged periods (1 - 31/2 yrs) even during the drug-free period; an observation which differs significantly from the Western studies, where the number of recurrences was not affected significantly once the continuous therapy with acyclovir was stopped. [1],[2],[4] Admittedly, the number of recurrences tend to diminish with time during the natural course of *the disease, but it would be difficult to explain such a dramatic reduction of recurrences of herpes genitalis lesions as seen in the present study on this basis alone. At present, there is no consensus on the optimal dosing schedule. The results of the present study show that a full therapeutic dose in the beginning followed by a suppressive dose, 200 mg 3 times daily for a minimum of 6 months, could be a good treatment schedule in patients of RHG. However, controlled studies with different dose schedule are required before reaching to any definite conclusion. Emergence of drug resistant strain remains a potental theoretical possibility of this form of therapy. [7] Another important limiting factor is the cost of the medicine.

 
  References Top

1.Douglas J M, Critchlow C, Benedeth J, et al. A double blind study of oral acyclovir for suppression of recurrent genital herpes simplex virus infection. New Eng J Med 1984; 310: 1551-6.  Back to cited text no. 1    
2.Straus S E, Takitt H E, Scidlin M, et al. Suppression of frequently recurring genital herpes. A placebo controlled double blind trial of oral acyclovir. New J Med 1984; 310 : 1545-50.  Back to cited text no. 2    
3.Mindel A, Weller IVD, Faherty A, et al. Prophylactic oral acyclovir in recurrent genital herpes. Lancet 1984; ii : 926 - 9.  Back to cited text no. 3    
4.Mindel A, Fajertu A, Carney 0, et al. Dosage and safety of long term suppression acyclovir therapy for recurrent genital herpes. Lancet 1988; i : 926 - 8.  Back to cited text no. 4    
5.Mindel A, Carney O, Sonnex C, et al. Suppression of frequently recurring genital herpes, acyclovir v/s inosine pronobex. Genitourin Med 1989; 65: 103-5.  Back to cited text no. 5    
6.Strans S E, Croen K D, Sawyer N, et al. Acyclovir suppression of frequently recurring genital herpes : efficacy and diminshing need during successive years of treatment JAMA 1988; 26: 227 - 30.  Back to cited text no. 6    
7.Collms P. Viral sensivity following introduction of acyclovir. Am J Med 1988; 85 (suppl 2A) : 123-8.  Back to cited text no. 7    


    Tables

[Table - 1]

This article has been cited by
1 Formulation and evaluation of acyclovir microcapsules using bakers yeast
Krishnan, P.N., Saraswathi, R., Dilip, C., Ramarao, N.
Asian Pacific Journal of Tropical Medicine. 2010; 3(6): 454-457
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article

    

Online since 15th March '04
Published by Wolters Kluwer - Medknow